Prosecution Insights
Last updated: November 17, 2026
Application No. 17/923,803

METHODS OF MONITORING KRAS MUTATIONS

Non-Final OA §112
Filed
Apr 28, 2023
Priority
May 08, 2020 — provisional 63/022,129 +1 more
Examiner
JOHNSON, CHRISTOPHER LINDSAY
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cardiff Oncology Inc.
OA Round
2 (Non-Final)
49%
Grant Probability
Moderate
2-3
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
18 granted / 37 resolved
-11.4% vs TC avg
Strong +79% interview lift
Without
With
+79.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
46 currently pending
Career history
88
Total Applications
across all art units

Office Action

§112
DETAILED ACTION This office action is in response to the Applicant’s filing dated June 9th, 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a 371 of PCT/US2021/031192 filed on May 6th, 2021; and has a PRO of 63/022,129 filed on May 8th, 2020. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Status of Claims Claims 1-2, 7, 18, 23, 47, 53-54, 56, 58-59, 63, 68 and 79-85 are pending in the instant application. Acknowledgement is made of Applicant’s remarks and amendments filed on June 9th, 2026. Acknowledgment is made of Applicant’s amendment of claims 1-2, 7 and 23; the cancelation of claims 5-6, 19, 30, 33, 36 and 40; and the addition of new claims 79-85. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-2, 7, 18, 23, 47, 53-54, 56, 58-59, 63 and 68 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claims 1-2, 7, 18, 23, 47, 53-54, 56, 58-59, 63 and 68, in claim 1 in line 10 spanning into line 16 the claim recites “wherein the cancer treatment with the PLK1 inhibitor is maintained (a) if the change in MAF of KRAS is a decrease of at least 25%, at least 50%, or at least 75%, or (b) if KRAS mutation in the samples decreases to below 0.01% or below 0.001% of KRAS in the sample; and wherein the cancer treatment with the PLK1 inhibitor is modified or discontinued if the change in MAF of KRAS is a decrease of less than 50%, less than 25%, or less than 10% or if KRAS mutation in the samples does not decrease to below 0.01% or below 0.001% of KRAS in the sample”. These claim limitations create a range overlap where it is not clear to one of ordinary skill in the art whether to maintain therapy, or modify or discontinue therapy, when there is a change in MAF of KRAS between 25-50%. The analysis must take into account which ranges one skilled in the art would consider inherently supported by the discussion in the original disclosure see MPEP § 2163.05(III). In this case, the instant specification provides no clarification of the conflicting guidance regarding the decision to either maintain therapy, or modify or discontinue therapy, when a change in MAF of KRAS in the overlapping range of 25-50% is encountered (paragraphs [0012, 0014, 0113-0114 and 0138]). Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 7 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Regarding claim 7, the claim fails to further limit the subject matter of the claim from which it depends. Specifically, it broadens how the Variant Allele Frequency (VAF) of KRAS gene is determined. Independent claim 1, from which this claim depends, specifically recites that VAF must be determined by Mutant Allele Frequency (MAF); however, the instant claim recites that VAF can be determined by total mutation count, MAF, number of KRAS mutation alleles per mL of plasma, or a combination thereof. Applicant may cancel the claim, amend the claim to place the claim in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements. Conclusion Claims 1-2, 7, 18, 23, 47, 53-54, 56, 58-59, 63, 68 and 79-85 is rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L JOHNSON whose telephone number is (571)272-1672. The examiner can normally be reached Monday - Friday 08:00AM - 5:00PM EST with Flex on Fridays. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.L.J./Examiner, Art Unit 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Apr 28, 2023
Application Filed
Mar 10, 2026
Non-Final Rejection mailed — §112
Jun 09, 2026
Response Filed
Sep 08, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790299
BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME
4y 11m to grant Granted Nov 10, 2026
Patent 12780818
EPOXYAMIDES AS KRAS G12C AND KRAS G12D INHIBITORS AND METHODS OF USING THE SAME
4y 6m to grant Granted Nov 03, 2026
Patent 12780812
PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12760025
SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF THERAPEUTIC USE THEREOF
3y 2m to grant Granted Oct 13, 2026
Patent 12746289
ANTITUMOR PHARMACEUTICAL COMPOSITION AND USE THEREOF
3y 4m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
49%
Grant Probability
99%
With Interview (+79.2%)
Moderate
PTA Risk
Based on 37 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month